Citations

Clear

2429 citation(s) found for "Shah, SS".

Creating a Mammography Conversation Aid for Shared Decision‐Making Between Clinicians and Women Aged 75 and Older
Schonberg, Mara A. , Stout, Natasha K. , Stein, Sarah , Corey, Matthew T. , Jushchyshyn, Jessica A., Shah, Ria , Wolfson, Emily A , Mandelblatt, Jeanne S. , Matlock, Daniel D. , Schechter, Clyde B., Harris, Russell, LeStage, Barbara , Schoenborn, Nancy L. , Matlock, Daniel D , Montori, Víctor M. , Richman, Ilana B. , Harris, Russell, Jayasekera, Jinani C.

Mayo Clinic

Journal of the American Geriatrics Society | April 15, 2025 | Volume: 73 | Issue: 7 | Pages: 2188-2195

10.1111/jgs.19466 | PMID 40231782 Get It

ABSTRACT Background Guidelines recommend primary care practitioners (“PCPs”) engage women ≥ 75 years in shared decision‐making (SDM) around mammography screening. Therefore, we aimed to develop a web‐based conversation aid about mammography screening for women ≥ 75 using output from established simulation models to provide screening outcomes based on > 23,000 combinations of individual women's health and breast cancer risk factors. Methods We used an end‐user centered design approach to develop a prototype web‐based conversation aid incorporating feedback. From July 2023 to April 2024, 10 PCPs from a Boston‐area health system and a safety‐net hospital used the prototype aid during encounters with women ≥ 75 without breast cancer or dementia ( n = 30; 1–5 patients per PCP). We observed aid use and assessed clinician effort to involve patients in SDM using OPTION5 (assesses five components of SDM, scores range 0–100). We surveyed PCPs and patients about the aid's acceptability. Patients completed the SDM‐process scale (scores range 0–4) to rate the SDM quality experienced. Participants' comments were subject to thematic analysis. Results Of 10 PCP ‐participants, seven were female and four were community‐based. Of 30 patient‐participants, 22 (73%) were non‐Hispanic White, 9 (30%) had ≥ 2 Charlson comorbidities and mean age was 78.5 years ( SD 2.8). Nine PCPs agreed that the aid helped them with SDM and was easy‐to‐use; six felt it had too much information; and seven planned to continue using the aid. Patients rated the SDM ‐process highly (scores = 3.0 [ SD 0.9]) and we observed high SDM (mean OPTION5 = 77.9 [ SD 20.6]). Participants felt the aid was “empowering” and “helpful for decision‐making.” After SDM discussions, seven patients intended to stop screening, nine to screen less frequently, and 14 to continue screening regularly. Conclusions We developed a novel conversation aid that supports SDM about mammography screening with women ≥ 75 years. Lessons learned will guide revisions of a final tool for testing in a clinical trial.
Efficacy and Toxicity Analysis of Selective BET Bromodomain Inhibitors in Models of Inflammatory Liver Disease
Doskey, Luke C. , Scholtz, Cole R. , Vail, Nora R. , Khanal, Shalil , Lee, Amani L. , Kandanur, Sai Giridhar Sarma , Hoell, Zachariah J. , Huehls, Amelia M. , Issa, Mohamed, Cao, Sheng , Shah, Vijay H. , Issa, Mohamed R , Reid, Joel M , Pomerantz, William C K , Lee, Amani , Kostallari, Enis , Reid, Joel M. , Malhi, Harmeet , Pomerantz, William C. K.

Mayo Clinic

Journal of Medicinal Chemistry | April 14, 2025 | Volume: 68 | Issue: 8 | Pages: 8091-8105

10.1021/acs.jmedchem.4c02555 | PMID 40227166 Get It

Clonal Hematopoiesis of Indeterminate Potential in Chronic Coronary Disease: A Report From the ISCHEMIA Trials Biorepository
Muller, Matthew , Liu, Richard , Shah, Farheen , Held, Claes , Kullo, Iftikhar J. , McManus, Bruce M. , Wallentin, Lars , Newby, L. Kristin , Sidhu, Mandeep S. , Muller, Matthew A , Hu, Jiyuan , Held, Claes , Kullo, Iftikhar J , Wallentin, Lars , Newby, L Kristin , Bangalore, Sripal , Reynolds, Harmony R , Hochman, Judith S , Maron, David J , Ruggles, Kelly V , Berger, Jeffrey S , Newman, Jonathan D , Bangalore, Sripal , Reynolds, Harmony R. , Hochman, Judith S. , Maron, David J. , Berger, Jeffrey S.

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 10, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.124.004921 | PMID 40207358 Get It

Genotype-specific neoplastic risk profiles in patients with VHL disease
Ganner, Athina , Sekula, Peggy , Schiavi, Francesca , Joo, Julia H. , Sansó, Gabriela , Almeida, Madson Q. , Knoblauch, Anna Laura, Gizaw, Christine Julia, Krzystolik, Karol , Astheimer, Sophie, Vieites, Ana , Donegan, Diane , Simsir, Ilgin Yildirim , Bandgar, Tushar , Pawlaczek, Agnieszka, Zandee, Wouter T. , Kater, Cláudio E. , Qi, Xiao-Ping , Deutschbein, Timo , Dallagnol, Tabatha Nakakogue , Yukina, Marina, Baudrand, René , Andreescu, Corina , Kunavisarut, Tada , Ishak, Nur Diana Binte , Horn, Xavier Le Guillon, Shutler, Gemma, Jovanović, Milan , Calissendorf, Jan, Circosta, Francesco , Bugalho, Maria João , Corssmit, Eleonora Pm, Goldmann, Andrea , Zovato, Stefania , Santana, Lucas Santos de , Freitas-Castro, Felipe , Rothermund, Christy A, Zimmermann, Josa, Aycut, Ayca, Vroonen, Laurent , Krauß, Tobias , Taschner, Christian , Ruf, Juri , Gläsker, Sven , Bucher, Felicitas , Agostini, Hansjürgen , Jilg, Cordula A. , Schultze‐Seemann, Wolfgang, Bausch, Birke, Bergfeld, Antonia, Rhein, Kilian , Fang, Xu-Dong , Kotsis, Fruzsina , Schäfer, Tobias, Links, Thera P. , Makay, Özer , Fagundes, Gustavo Freitas Cardoso, Shah, Nalini , Barontini, Marta, Larsson, Catharina , Januszewicz, Andrzej , Lima, José Viana , Cybulski, Cezary, Walz, Martin K. , Koettgen, Anna, Neumann, Hartmut P.H., Neumann‐Haefelin, Elke , Köttgen, Anna , Yukina, M. Yu. , Sekula, Peggy , Almeida, Madson Q , Juhlin, Carl Christofer , Ngeow, Joanne , Eng, Charis , Baudrand, Rene , Ferrara, Alfonso Massimiliano , Steiert, Christine , Achatz, Maria Isabel , Hundsberger, Thomas , Lubiński, Jan , Hasse-Lazar, Kornelia , Yu, Kai , Rostomyan, Liliya , Remde, Hanna , Horn, Xavier Le Guillou , Jovanovic, Milan, Pęczkowska, Mariola , Calissendorff, Jan , Gimm, Oliver , Quinkler, Marcus , Watutantrige‐Fernando, Sara , Rothermundt, Christian Alexander , Zimmermann, Josa, Durmaz, Asude , Klingler, Jan‐Helge , Lang, Stefan Johann , Bergfeld, Antonia, Uslar, Thomas , Concistrè, Antonio , Juhlin, C. Christofer , Rocha, José Cláudio Casali da , Petramala, Luigi , Tsoy, U. A. , Grineva, Elena , Fagundes, Gustavo F C , Ngeow, Joanne , Opocher, Giuseppe , Wohllk, Nelson , Letizia, Claudio , Donatini, Gianluca , Maher, Eamonn R. , Beltsevich, D. G. , Bancos, Irina , Eng, Charis

Mayo Clinic

Endocrine-Related Cancer | April 9, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1530/erc-24-0260 | PMID 40202835 Get It

Abstract Hereditary tumor predisposition syndromes pose a challenge for early detection and timely treatment of tumors. In von Hippel–Lindau disease, desirable personalized surveillance programs are lacking due to insufficient data on genotype-specific risk profiles of individual mutations. To describe neoplastic risk profiles for carriers of pathogenic and likely pathogenic VHL germline mutations, our observational study recruited 1,350 participants from 40 centers worldwide. 432 different VHL germline mutations were observed, with p.Asn78Ser, p.Arg161Ter, p.Arg161Gln, p.Arg167Gln, p.Arg167Trp and p.Tyr98His being the six most frequent, occurring in a total of 493 carriers (36.5%) and in ≥30 patients each. Age-related penetrance risks for retinal hemangioblastoma, central nervous system hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumors and pheochromocytoma/paraganglioma in carriers of the most frequent VHL mutations were assessed. In addition, the number of organs affected, the frequency of surgery and the outcome are reported. Pairwise comparisons of the age-dependent tumor penetrance of these six mutations showed that 47 out of 90 pairs were significantly different. The most significant associations were found in p.Tyr98His (n = 19), followed by p.Arg161Ter (n = 10). All pairwise comparisons of mutations affecting different codons showed at least one significant (P < 0.05) difference, except for p.Asn78Ser vs p.Arg161Ter. Thus, tumor risk varied by VHL mutation type and location, but did not differ between the truncating mutation p.Arg161Ter and the missense mutation p.Asn78Ser. Our study demonstrates the importance of mutation-specific phenotype prediction. With appropriate validation, the data have important implications for risk assessment and decision making in tumor prevention for carriers of the respective VHL mutations.
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Lin, Daniel W. , Feldman, Darren R., Aggarwal, Rahul , Drakaki, Alexandra , Eggener, Scott E. , Humphrey, Peter A. , Leuva, Harshraj , Levine, Ellis G., Maughan, Benjamin L. , Reichert, Zachery R. , Rwigema, Jean‐Claude M. , Shah, Sumit, Singla, Nirmish, Sircar, Kanishka , Zhumkhawala, Ali , Sliker, Bailee , Gilligan, Timothy D. , Adra, Nabil , Bagrodia, Aditya , Yamoah, Kosj , Chandrasekar, Thenappan , Costa, Daniel Nobrega da , Drakaki, Alexandra , Emamekhoo, Hamid , Geynisman, Daniel M. , Graham, Laura , Luckenbaugh, Amy N. , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Rais‐Bahrami, Soroush , Saylor, Philip J. , Shah, Ankeet , Shah, Sumit, VanderWeele, David James , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0018 | PMID 40203876 Get It

The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.
Using Large-scale Contrastive Language-Image Pre-training to Maximize Brain MRI-Based Headache Classification (P4-12.007)
Rafsani, Fazle , Sheth, Devam, Che, Yiming , Shah, Jay , Nikolva, Simona, Sheth, Devam, Siddiquee, Md Mahfuzur Rahman , Chong, Catherine D. , Dumkrieger, Gina , Li, Baoxin , Wu, Teresa , Schwedt, Todd J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210540 Get It

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of <40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Response to Letter to the Editor From Zhang et al: “Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer”
Konda, Bhavana , Sherman, Eric J. , Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 4, 2025 | Volume: 110 | Issue: 7 | Pages: e2425-e2426

10.1210/clinem/dgaf221 | PMID 40184489 Get It